Nothing Special   »   [go: up one dir, main page]

SG11202104734YA - Cholix-derived carriers for oral delivery of heterologous payload - Google Patents

Cholix-derived carriers for oral delivery of heterologous payload

Info

Publication number
SG11202104734YA
SG11202104734YA SG11202104734YA SG11202104734YA SG11202104734YA SG 11202104734Y A SG11202104734Y A SG 11202104734YA SG 11202104734Y A SG11202104734Y A SG 11202104734YA SG 11202104734Y A SG11202104734Y A SG 11202104734YA SG 11202104734Y A SG11202104734Y A SG 11202104734YA
Authority
SG
Singapore
Prior art keywords
cholix
oral delivery
heterologous payload
derived carriers
carriers
Prior art date
Application number
SG11202104734YA
Inventor
Amir Porat
Randall J Mrsny
Charles Olson
Derek Maclean
Sally Postlethwaite
Original Assignee
Applied Molecular Transport Inc
Randall J Mrsny
Charles Olson
Derek Maclean
Sally Postlethwaite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/021474 external-priority patent/WO2019173787A1/en
Application filed by Applied Molecular Transport Inc, Randall J Mrsny, Charles Olson, Derek Maclean, Sally Postlethwaite filed Critical Applied Molecular Transport Inc
Publication of SG11202104734YA publication Critical patent/SG11202104734YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202104734YA 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload SG11202104734YA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07
US201962816022P 2019-03-08 2019-03-08
PCT/US2019/021474 WO2019173787A1 (en) 2018-03-08 2019-03-08 Toxin-derived delivery constructs for oral delivery
US201962888133P 2019-08-16 2019-08-16
US201962888400P 2019-08-16 2019-08-16
US201962888144P 2019-08-16 2019-08-16
PCT/US2019/050708 WO2020096695A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload

Publications (1)

Publication Number Publication Date
SG11202104734YA true SG11202104734YA (en) 2021-06-29

Family

ID=70611452

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104734YA SG11202104734YA (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload

Country Status (15)

Country Link
US (3) US11324833B2 (en)
EP (1) EP3826682A4 (en)
JP (2) JP7487193B2 (en)
KR (1) KR20210110800A (en)
CN (1) CN113347997A (en)
AU (1) AU2019374703A1 (en)
BR (1) BR112021009001A8 (en)
CA (1) CA3119179A1 (en)
CL (1) CL2021001210A1 (en)
CO (1) CO2021007359A2 (en)
IL (1) IL282986B2 (en)
MX (1) MX2021005382A (en)
SG (1) SG11202104734YA (en)
TW (1) TW202031297A (en)
WO (1) WO2020096695A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
KR102598038B1 (en) 2014-05-07 2023-11-07 어플라이드 몰레큘라 트랜스포트 인크. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP4316586A3 (en) 2018-03-08 2024-05-08 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
AU2019377117A1 (en) 2018-11-07 2021-06-10 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
TW202120521A (en) 2019-08-16 2021-06-01 美商應用分子運輸公司 Compositions, formulations, and interleukin production and purification
JP7420924B2 (en) * 2020-03-31 2024-01-23 平田機工株式会社 Method for producing recycled asphalt mixture and method for analyzing waste material of asphalt mixture
KR20240118914A (en) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 Compositions and methods for the treatment of metabolic and liver disorders
AR124877A1 (en) * 2021-02-16 2023-05-17 Applied Molecular Transport Inc SOLID ORAL COMPOSITIONS WITH ZINC
WO2022241167A1 (en) * 2021-05-12 2022-11-17 Applied Molecular Transport Inc. Delivery constructs derived from bacterial toxins and uses thereof
WO2022240407A1 (en) * 2021-05-12 2022-11-17 Applied Molecular Transport Inc. Delivery constructs derived from bacterial toxins and uses thereof
WO2023141527A1 (en) * 2022-01-21 2023-07-27 Applied Molecular Transport Inc. Furin-cleavable delivery constructs
CN114470170B (en) * 2022-02-22 2023-09-19 广州新济药业科技有限公司 Semiglutide soluble microneedle composition and preparation method thereof
WO2023196532A1 (en) * 2022-04-08 2023-10-12 Applied Molecular Transport Inc. Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0531434B1 (en) 1990-05-11 1999-07-14 THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
US5328984A (en) 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
CA2077277A1 (en) 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
WO1993025690A1 (en) 1992-06-18 1993-12-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US20020034727A1 (en) 1992-11-02 2002-03-21 Genentech, Inc. Compaction assay for assessment of respiratory disease therapy
US5811409A (en) 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6086900A (en) 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
CA2295971C (en) 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
DE69836024T2 (en) 1997-07-11 2007-09-27 The United States Government As Represented By The Department Of Health And Human Services PSEUDOMONAS EXOTOXIN A-SIMILAR CHIMERIC IMMUNOGENES FOR TRIGGERING A SECRETARY IGA-MEDIATED IMMUNE RESPONSE
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6838553B1 (en) 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7824695B1 (en) 1999-10-22 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Delivery of proteins across polar epithelial cell layers
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7314625B2 (en) 2000-12-21 2008-01-01 The United States As Represented By The Secretary Of The Department Of Health And Human Services Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7595054B2 (en) 2003-06-09 2009-09-29 Healthbanks Biotech Co., Ltd. Fusion antigen used as vaccine
US8206950B2 (en) 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
EP1522585A1 (en) 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
US20080317761A1 (en) 2004-04-28 2008-12-25 The Trustees Of The University Of Pennsylvania Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
BRPI0512235A (en) * 2004-06-18 2008-02-19 Ambrx Inc antigen-binding polypeptides and their uses
US20050281885A1 (en) 2004-06-21 2005-12-22 Egilmez Nejat K Method for treating inflammatory bowel disease by oral administration of IL-10
TWI293957B (en) 2004-07-21 2008-03-01 Healthbanks Biotech Co Ltd A superantigen fusion protein and the use thereof
JP4474264B2 (en) 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 Fusion protein of cervical cancer suppression
WO2006135428A2 (en) 2004-10-04 2006-12-21 Trinity Biosystems, Inc. Methods and compositions for inducing an immune response against multiple antigens
CA2583226A1 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
US20090285771A1 (en) 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2006109303A2 (en) 2005-04-11 2006-10-19 Yeda Research And Development Co.Ltd. Chimeric proteins comprising yersinia yop, their preparation and pharmaceutical compositions containing them
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
US8907060B2 (en) 2005-07-29 2014-12-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutated Pseudomonas exotoxins with reduced antigenicity
EP1749833A1 (en) 2005-08-05 2007-02-07 Healthbanks Biotech Co., Ltd. Super-antigens derived from the SARS coronavirus E2 spike protein
EP1757615B1 (en) 2005-08-24 2011-08-24 Healthbanks Biotech Co., Ltd. Fusion protein for inhibiting cervical cancer
CN101547702B (en) 2005-09-06 2016-06-22 奥拉姆德医药公司 For oral administration method of protein and compositions
CA2631981A1 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US7666991B2 (en) 2005-12-05 2010-02-23 Trinity Biosystems, Inc. Compositions for needleless delivery of antibodies
EP2010205A2 (en) 2006-03-16 2009-01-07 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US7465455B2 (en) 2006-07-05 2008-12-16 Healthbanks Biotech Co., Ltd. Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
ATE550033T1 (en) 2006-07-29 2012-04-15 Healthbanks Biotech Co Ltd FUSION PROTEINS OF THE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS FROM PORK AS A PRRS VACCINE
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
US20100196277A1 (en) 2006-10-09 2010-08-05 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
EP2164989B1 (en) 2007-05-23 2018-01-24 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
WO2009014650A2 (en) * 2007-07-20 2009-01-29 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
US20090203884A1 (en) 2008-01-31 2009-08-13 Healthbanks Biotech Co., Ltd. Chimeric hiv fusion proteins as vaccines
CA2712511A1 (en) 2008-03-17 2009-09-24 Universitaetsklinikum Muenster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
WO2009149281A1 (en) 2008-06-04 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins and uses thereof
KR101671540B1 (en) 2008-10-21 2016-11-01 국제백신연구소 A1 moiety of cholera toxin a subunit as an adjuvant for mucosal and systemic vaccines
CA2768598A1 (en) 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AU2011302645B2 (en) * 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
JP2014505064A (en) 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー Delivery systems and conjugates for delivering compounds via naturally occurring intracellular transport pathways
WO2012110596A1 (en) 2011-02-16 2012-08-23 Friedrich-Alexander-Universität Erlangen-Nürnberg Fusion protein for the treatment of immunologic or allergic reactions
PT2726091T (en) 2011-06-29 2020-04-22 Rani Therapeutics Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
UA113192C2 (en) 2011-12-06 2016-12-26 IMMUNOGENIC COMPOSITION AGAINST PIG TYPE 2 (PCV2) CIRCULOSIS
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
CN107434827B (en) 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 Fusion proteins as immunogenic enhancers for inducing antigen-specific T cell responses
UA118843C2 (en) 2013-03-15 2019-03-25 Дженентек, Інк. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
JP2016526014A (en) 2013-04-24 2016-09-01 アルモ・バイオサイエンシーズ・インコーポレイテッド Interleukin-10 composition and use thereof
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
CN103864938A (en) 2014-03-24 2014-06-18 北京博翱泰生物技术有限公司 Target-specificity double-mutant fused protein and preparation process thereof
KR102598038B1 (en) 2014-05-07 2023-11-07 어플라이드 몰레큘라 트랜스포트 인크. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2017004983A (en) 2014-10-22 2017-11-13 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders.
TWI806150B (en) 2014-11-07 2023-06-21 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
WO2016146833A1 (en) * 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
JP6676661B2 (en) 2015-06-01 2020-04-08 リーバー ジェネティクス シーオー．， エルティーディー．Ｒｅｂｅｒ Ｇｅｎｅｔｉｃｓ Ｃｏ．， Ｌｔｄ． Vaccine composition against porcine genital respiratory syndrome and porcine circovirus-related disease
CA3009127A1 (en) 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2018015380A1 (en) 2016-07-18 2018-01-25 Philippe Ulsemer Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors
TW201829470A (en) 2016-10-26 2018-08-16 廖朝暐 Fusion polypeptide for immuno-enhancement and method for enhancing stimulation of immune response using the same
IL293710B2 (en) 2016-12-07 2024-10-01 Molecular Templates Inc Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3668544A1 (en) 2017-08-15 2020-06-24 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
US11674950B2 (en) 2017-10-31 2023-06-13 Dana-Farber Cancer Institute, Inc. Methods determining and treating cellular resistance to ADP-rtbosylating toxin
US20200354411A1 (en) 2017-11-29 2020-11-12 Agency For Science, Technology And Research Chimeric Molecule for Targeting c-Myc in Cells
WO2019133647A1 (en) 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses
EP4316586A3 (en) * 2018-03-08 2024-05-08 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
AU2019230230A1 (en) * 2018-03-08 2020-10-22 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
WO2020023389A1 (en) 2018-07-23 2020-01-30 Sienna Biopharmaceuticals, Inc. Reduced exposure compositions modulating therapeutic targets
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
AU2019377117A1 (en) 2018-11-07 2021-06-10 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
US20200140511A1 (en) 2018-11-07 2020-05-07 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
WO2020229964A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
TW202120521A (en) 2019-08-16 2021-06-01 美商應用分子運輸公司 Compositions, formulations, and interleukin production and purification
US20210100887A1 (en) 2019-10-04 2021-04-08 Reber Genetics Co., Ltd. Recombinant fusion protein and immunogenic composition

Also Published As

Publication number Publication date
JP2024097890A (en) 2024-07-19
BR112021009001A2 (en) 2021-08-17
CA3119179A1 (en) 2020-05-14
CO2021007359A2 (en) 2021-06-21
IL282986A (en) 2021-06-30
AU2019374703A1 (en) 2021-06-24
US20240009316A1 (en) 2024-01-11
US20210100911A1 (en) 2021-04-08
US11324833B2 (en) 2022-05-10
US20210187113A1 (en) 2021-06-24
IL282986B1 (en) 2023-09-01
MX2021005382A (en) 2021-11-12
JP2022512976A (en) 2022-02-07
CL2021001210A1 (en) 2021-11-05
WO2020096695A1 (en) 2020-05-14
IL282986B2 (en) 2024-01-01
KR20210110800A (en) 2021-09-09
US11504433B2 (en) 2022-11-22
TW202031297A (en) 2020-09-01
EP3826682A1 (en) 2021-06-02
EP3826682A4 (en) 2021-11-17
CN113347997A (en) 2021-09-03
BR112021009001A8 (en) 2021-10-26
JP7487193B2 (en) 2024-05-20

Similar Documents

Publication Publication Date Title
IL282986A (en) Cholix-derived carriers for oral delivery of heterologous payload
IL269209A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
IL275989B (en) Encapsulated cannabinoid formulations for oral delivery
PT3762009T (en) Toxin-derived delivery constructs for oral delivery
EP3703743A4 (en) Methods of oral immunotherapy
IL282773A (en) Edaravone suspension for oral administration
IL277209A (en) Toxin-derived delivery constructs for oral delivery
EP3328315A4 (en) Package for orthodontic brackets
ZA202006128B (en) Method for preparing pyrroloaminopyridazinone compound and intermediates thereof
EP3863609A4 (en) Small polymeric carriers for delivery of agents
EP3682016A4 (en) Formulations for compound delivery
EP3854725C0 (en) Delivery station
EP3875088A4 (en) Package for medical composition containing anti-tumor agent
EP3787391C0 (en) Harvester for straw-like material
GB201903229D0 (en) Immunotherapy
IL284816A (en) Methods for improved immunotherapy
EP3638307C0 (en) Stable pooled breastmilk antibodies for oral delivery
GB2572137B (en) Delivery apparatus
ZA202007318B (en) Dental fluoro-aluminosilicate glass powder
KR102388028B9 (en) Composition for delivering of polypptide
SG10201910880QA (en) Dicing apparatus
GB2577558B (en) Substance delivery devices
FI12579U1 (en) Arrangement for serving of bevarage packages
GB201806819D0 (en) Compositions for active immunotherapy
GB201905065D0 (en) Oral station